Phase 2 Study of TD-9855 to Treat Fibromyalgia

PHASE2CompletedINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions
Fibromyalgia
Interventions
DRUG

TD-9855 Group 1

DRUG

TD-9855 Group 2

DRUG

Placebo

Trial Locations (34)

14221

Upstate Clinical Research Associates, LLC, Williamsville

16635

Altoona Center for Clinical Research, Duncansville

27103

The Center for Clinical Research, Winston-Salem

27612

Wake Research Associates, Raleigh

29464

Coastal Carolina Research Center, Mt. Pleasant

29732

Carolina Center for Rheumatology & Arthritis Care, Rock Hill

32806

Compass Research, LLC, Orlando

33511

PAB Clinical Research, Brandon

33805

Meridien Research, Lakeland

34201

Florida Clinical Research Center, LLC, Bradenton

34471

Renstar Medical Research, Ocala

35801

Rheumatology Associates of North Alabama, PC, Huntsville

37421

ClinSearch, LLC, Chattanooga

43551

Clinical Research Source, Inc., Perrysburg

45219

University of Cincinnati, Cincinnati

47714

MediSphere Medical Research Center, LLC, Evansville

57049

Meridian Clinical Research, Dakota Dunes

58103

Lillestol Research, LLC, Fargo

60031

Clinical Investigation Specialists, Inc., Gurnee

64114

The Center for Pharmaceutical Research, Kansas City

66218

GTC Research, Shawnee Mission

68134

Meridian Clinical Research, Omaha

74104

Tulsa Clinical Research, LLC, Tulsa

85395

Dedicated Clinical Research, Goodyear

89123

Advanced Biomedical Research of America, Las Vegas

92020

TriWest Research Associates, LLC, El Cajon

93449

Arroyo Medical Group, Inc., Pismo Beach

94598

Diablo Clinical Research, Inc., Walnut Creek

97504

Sunstone Medical Research, LLC, Medford

98104

Swedish Rheumatology Research, Seattle

06320

Coastal Connecticut Research, LLC, New London

02301

Beacon Clinical Research, Brockton

02740

Beacon Clinical Research, New Bedford

02886

Omega Medical Research, Warwick

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY